[Skip to Content]

Upstate Active Clinical Trials

Study Title:

A051301: A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologus Stem Cell Transportation Versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype

What is the purpose of the study?

The purpose of this study is to directly compare any good and bad effects of using an oral medication, ibrutinib, along with the AutoHCT versus AutoHCT alone. Ibrutinib is a cancer drug that may be effective against a certain type of DLBCL called “Activated B-Cell Subtype” (or “ABC”). Ibrutinib may be effective for patients who relapse after AutoHCT. Ibrutinib is already FDA-approved for use in patients with other types of cancers, such as chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom’s Macroglobulinemia.

Upstate Institutional Review Board (IRB) Number:

933193

Study/Protocol ID:

A051301

Study Phase:

Phase III

Patient Age Group:

Adults

Principal Investigator:

Teresa C Gentile, MD, PhD

Where will the study take place?

Upstate Cancer Center, The Hill medical Center, Oswego, Oneida

ClinicalTrials.Gov ID:

NCT02443077

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Corey Chase
Phone: 315-464-4187
Email: chasec@upstate.edu

Return to Previous Page || Search Again

Top